Somatostatin receptors are present in the normal adrenal cortex and medulla. These receptors are also expressed by tumors that cause Cushing's syndrome and by pheochromocytomas. Somatostatin analogues such as octreotide have been developed to target somatostatin receptors for diagnostic and therapeutic purposes. This article reviews the current knowledge of the biology of somatostatin receptors in the normal adrenal gland and in adrenal tumors and defines the current role of the somatostatin receptor in the diagnosis, staging and management of Cushing's syndrome and pheochromocytomas.
INTRODUCTION
The adrenal glands are paired endocrine glands located atop the kidneys. Each adrenal gland has a cortex and a medulla. The adrenal cortex is subdivided into three layers, each with a distinct role in hormone production. The outermost "zona glomerulosa" is the site of aldosterone production, the middle "zona fasciculata" produces cortisol and the innermost "zona reticularis" is the site of adrenal androgen production. The adrenal medulla is part of the neuroendocrine system, receiving sympathetic innervation and producing catecholamines, epinephrine and norepinephrine. Researchers have begun to investigate the importance of the presence of somatostatin hormone receptors on adrenal tissues. The purpose of this article is to review what is currently known about the presence of somatostatin receptors in normal adrenal tissue and adrenal tumors. Next, the use of radiolabeled somatostatin analogues for the diagnosis of adrenal pathology will be discussed. Finally, the potential use of somatostatin analogues for the treatment of adrenal disorders will also be addressed.
NORMAL ADRENAL SOMATOSTATIN RECEPTORS Somatostatin, also called somatotropin releasing inhibitory hormone (SRIH)b, is a peptide hormone that is present in two predominant isoforms: a 14 amino acid structure and a 28 amino acid form [1, 2, 3] . Each of these naturally occur- ring isoforms binds to all five of the known somatostatin receptors (SSTR1I5) that have been identified in humans [4] . When five normal human adrenals were examined by a To whom all correspondence should be addressed: John W. Kennedy SRS, somatostatin receptor scintigraphy; MBq, milli-barq; llIn-DPTA-Phe1-octreotide, indium 11 l-diethylene triamine penta-acetic acid phenylalanine-l-octreotide; mCi, milli-Curie; 131I-MIBG, radioautography for specific binding of radiolabeled somatostatin (1251-SRIH), somatostatin receptors were identified in both cortex and medulla, but specific binding was much more intense in the normal human adrenal medulla [5] . In a study of two normal human adrenal glands, messenger ribonucleic acid (mRNA) for each of the five SSTR subtypes was expressed, with SSTR2 predominating [5] . In summary, the normal human adrenal gland contains all five of the known somatostatin receptor subtypes. The predominant isoform is SSTR2, and the receptors are concentrated in the adrenal medulla.
Animal studies have been performed in an attempt to gain further insight into the role of somatostatin receptors within the adrenal cortex. In salt-depleted rats, the site of highest somatostatin receptor density in the adrenal cortex is the zona glomerulosa [6, 7] . Administration of somatostatin to these animals specifically inhibits angiotensin II-stimulated aldosterone production. In addition, somatostatin inhibits the basal and angiotensin II-stimulated growth of the rat zona glomerulosa [8] . These animal studies demonstrate that under the given experimental conditions, rat adrenal cortical somatostatin receptors are located mainly in the zona glomerulosa, regulating angiotensin Il-mediated aldosterone secretion and growth of the adrenal cortex.
SOMATOSTATIN RECEPTORS AND ADRENAL DISEASE

Pheochromocytomas
Pheochromocytomas are neuroendocrine tumors arising from the adrenal medulla, which characteristically overs-secrete catecholamines, producing a clinical syndrome of paroxysmal hypertension, heart palpitations and profuse sweating [9, 10] . Paragangliomas are similar tumors, which arise from sympathetic ganglionic tissue and are also known as ectopic or extra-adrenal pheochromocytomas. Approximately 10 percent of pheochromocytomas are malignant. In a study of 51 adrenal pheochromocytomas (46 benign and five malignant), 37 of 51 had SRIH receptors (73 percent) detectable by 125I-SRIH radioautography. Only 36 percent of the tumors studied were classified as containing a high density of receptors [11] . However, 13 of 14 paragangliomas studied in the same paper were SRIH receptor positive (93 percent), with 43 percent considered to be of high density.
In a separate study of 33 human pheochromocytomas (22 benign adrenal, six extraadrenal and five malignant), SSTR was detected in all tumors, but 12/33 pheochromocytomas had a receptor density that was at or below the normal range [5] . In these same tumors, specific binding of radiolabeled somatostatin (1251-SRIH) was found to be evenly distributed over the tumor tissue and was on average significantly increased (two-fold) over normal adrenal medullary tissue. There was no detectable difference in the density of SSTR expression among the subgroups of pheochromocytomas studied. A substudy of SSTR mRNAs quantified by amplification of their respective cDNAs in eight pheochromocytomas (four benign adrenal, two benign extra-adrenal and two malignant), reported in the same paper, revealed that all five SSTR subtypes may be expressed by pheochromocytomas, with multiple subtypes expressed by a single tumor. This confirmed a previous study by a separate group who identified multiple SSTRI and SSTR2 isoforms in each three of the three pheochromocytomas examined [12] . The predominant somatostatin receptor subtypes expressed by pheochromocytomas are SSTR2 and SSTR4 [5] . Patients are diagnosed with ACTH-dependent Cushing's Syndrome based upon elevated serum or urine cortisol measurements, with simultaneous elevation of ACTH [14] . Further biochemical suppression tests are then performed in an attempt to differentiate the source of the abnormal hormone production either to the pituitary or periphery [14, 15] . When these studies are non-diagnostic, the pituitary may be visualized with magnetic resonance imaging (MRI) to attempt to identify obvious disease. In equivocal cases, inferior petrosal sinus (IPS) sampling for ACTH with and without CRH stimulation is performed to document whether the excess hormone production is of a central pituitary or peripheral ectopic source [16] . It is in those cases isolated to the periphery that somatostatin receptor scintigraphy has been of most diagnostic benefit.
Initial evidence for the potential benefit of SRS was tested in a study of 10 patients with ectopic Cushing's syndrome (nine ectopic ACTH-secreting tumors and one CRHsecreting tumor) with a total of 24 known localizations and one occult tumor. In five of the 10 patients, SRS identified all known localizations, and in eight of 10, identified at least one known site. Nineteen of the 24 known localizations were correctly identified (79 percent) [17, 18] . The one occult tumor remained occult despite the octreotide scan. No information about possible false-positive localizations was included in the report. Thus, this report suggested that in up to 79 percent of lesions may be identified by SRS in cases of ectopic Cushing's, localizing all sites in 50 percent of subjects. In this same study, nine other patients with pituitary or adrenal sources for their excess hormone production (five pituitary Cushing's disease, three Nelson's syndrome and one adrenal adenoma) had negative scans, suggesting these tumors do not overexpress somatostatin receptors.
Actual tumor size is of little importance in octreotide scanning. It is the increased density of somatostatin receptors expressed by the tumors compared with neighboring tissues that allows the tumor to be visualized [19] . For this reason, tiny producing tumors that overexpress somatostatin receptors may be easily visualized with octreotide scanning. Three additional case reports have been published in which SRS localized minute carcinoid tumors (1.0 cm, 0.9 cm and 0.6 cm) that were responsible for ACTH-dependent Cushing's syndrome in patients. [20, 21, 22] . SRS identification (two patients) and confirmation (one patient) of these small lesions was clinically important as their signal characteristics were difficult to distinguish from pulmonary blood vessels by conventional imaging, and surgical removal of these lesions leads to prompt cure. SRS and pheochromocytoma
Despite the extensive in vitro data that has been published regarding the presence of somatostatin receptors on pheochromocytomas, the published clinical experience with somatostatin analogues such as radiolabeled octreotide to image pheochromoctomas in vivo has been limited to two small European case series. In the largest series published to date, 12 out of 14 pathologically confirmed pheochromocytomas (86 percent) were identified by lllln-DPTA-Phel-Octreotide (222 MBq intravenous with planar imaging four hours post-injection and planar plus SPECT imaging at 24 hours) [23] . This same group reported a diagnostic sensitivity of 93 percent for the localization of paragangliomas (26 out of 28) using the same protocol [23, 24] . No information regarding false positive localizations was stated.
Our own preliminary experience with SRS and pheochromocytomas involves an ongoing comparison of SRS with standard imaging modalities (CT or MRI) at the Brigham and Women's Hospital in Boston [25] . Patients with a high clinical suspicion of pheochromocytoma based upon biochemical testing and the presence of a CT or MRI documented lesion underwent SRS (6.0 mCi I1IIn-pentetreotide with planar imaging at four and 24 hours and SPECT imaging at 24 hours). All suspicious lesions were then evaluated at surgery and identified with pathology. SRS accurately localized five of six pheochromocytomas. Two benign lesions felt to be suspicious for pheochromocytoma based on MRI were appropriately negative on SRS. Thus, this small series demonstrates that SRS has a sensitivity of 83 percent for pheochromocytoma (five of six lesions), comparable to the European experience. In our experience, SRS localizes adrenal, ectopic and metastatic pheochromocytomas. Prospective multi-center studies are needed in order to obtain the necessary numbers of patients to more firmly establish the sensitivity and specificity of this test.
The other published study addresses the important clinical consideration of the relative sensitivity of SRS compared to the current gold standard nuclear medicine compound utilized in the evaluation of pheochromocytoma, MIBG [26] . The sensitivity of MIBG scanning for pheochromocytoma has been well established, based in part on a prospective study of 109 patients with a high clinical suspicion for pheochromocytoma who received extensive biochemical testing, CT scanning and a diagnostic 131I-MIBG (45 surgically confirmed cases of pheochromocytoma, 20 non-pheochromocytoma adrenal masses and 44 considered clinically free of disease based on the diagnostic workup) [9] . MIBG blinded investigators, and sites were confirmed by histologic examination of surgical specimens for chromaffin tissue when available. SRS identified at least one lesion in nine of 10 subjects with pheochromocytoma while MIBG identified tumor in eight of 10. MIBG, however, localized over 80 lesions in these patients, while octreotide only identified 28. Soft tissue lesions were identified equally well with both techniques, although in general, the intensity of uptake was greater for MIBG. MIBG was superior, though, for the localization of bone metastases [26] . Overall, octreotide identified only 43 percent of sites seen by the diagnostic MIBG scans, and only 24 percent of the sites identified on therapeutic MIBG. Octreotide scanning fared far better in the three subjects with paragangliomas identifying at least one site in all three patients and eight sites overall, compared to the nine sites seen by MIBG in the three subjects.
There was one pathologically confirmed lung metastasis that was missed by MIBG but identified by octreotide. However, the abdominal primary in this same patient was missed by octreotide but seen on MIBG. This raises the possibility that octreotide scanning may be complementary to MIBG scintigraphy. This concept was tested further by Krenning and colleagues in an analysis of eight patients with pheochromocytoma and four subjects with paraganglioma. Two patients with pheochromocytoma who received both scans had more lesions seen with octreotide, while two had more lesions seen with MIBG. Four patients had the same number of lesions visualized. Three out of four patients with paragangliomas had more sites identified with octreotide than MIBG [23] . Therefore, the sensitivity of these nuclear imaging techniques appears to depend on type of tumor and suspected location of metastases. MIBG appears more sensitive for pheochromocytoma metastases to bone, while octreotide may be preferred for pheochromocytoma metastases to lung and for cervical paragangliomas [23, 26] . Future studies comparing SRS to MIBG utilizing a consistent amount of nucleotide in each subject are needed to more accurately assess the relative sensitivities of these techniques as dosimetry affects the diagnostic sensitivity of radionucleotide imaging. Clinical algorithms for SRS in Cushing's syndrome and pheochromocytoma A critical question for the clinician is the appropriate use of radionuclide imaging in the management of a patient with either a suspected or pathologically confirmed case of Cushing's or pheochromocytoma. Until further prospective studies are completed, which would establish the sensitivity, specificity and cost effectiveness of SRS, clinical judgment will dictate its use on a case-by-case basis [27] .
The diagnosis of ACTH-dependent Cushing's syndrome should be established biochemically prior to any imaging being performed ( Figure 1 ). Next, a dexamethasone suppression test and a pituitary MRI is performed to localize the lesion. A diagnostic suppression test in conjunction with a localization by pituitary MRI is followed directly by surgical resection of the identified lesion. Negative pituitary MRI in conjunction with nondiagnostic suppression or markedly elevated ACTH levels strongly suggests a peripheral source and should be initially followed by SRS and chest and abdominal CT scans to localize the tumor. A positive localization will avoid the invasive IPS [16] .
are resected. Pheochromocytomas and paragangliomas should first be diagnosed biochemically and then localized with MRI ( Figure 2 ). If a benign appearing adrenal mass is identified, the patient may proceed directly to surgical resection. If no mass is seen, an octreotide scan or MIBG scan is performed to localize the source. Choice of scan depends upon availability and local expertise. A positive scan avoids the need for invasive venous sampling. In adults, 10 percent of pheochromocytomas may be ectopic, 10 percent malignant and 10 percent bilateral [10] . Extra-adrenal and malignant lesions identified by MRI should be confirmed with nuclear imaging to document the neuroendocrine nature of the lesions and to rule out extra-abdominal metastases. Patients with persistent post-resection hypertension and catecholamine excess would also benefit from a follow-up nuclear scan to rule out recurrent or residual disease that may be obscured by post-operative changes [20] .
CURRENT SENSITIVITY AND SPECIFICITY OF SRS Several caveats must be kept in mind when using somatostatin receptor scintigraphy for the identification of adrenal tumors. There has been no study published to date that adequately addresses the specificity of SRS. It is known, however, that activated lymphocytes overexpress somatostatin receptors. Positive octreotide scans, therefore, occur in sites of granulomatous disease (23 of 23 cases of sarcoid, four of four cases of Wegener's, and six of six cases of tuberculosis) and in cases of autoimmune inflammation (nine of nine cases of untreated Graves' hyperthyroidism) [23] . Localized sites of abscess or infection or active sites of rheumatoid arthritis will also result in a positive scan. Up to 75 percent of benign, non-functioning pituitary adenomas may overexpress somatostatin receptors (12 of 16) [23] .
The current clinical case series published to date suggest a diagnostic sensitivity of up to 86 percent for benign pheochromocytomas but as low as 24 percent for pheochromocytoma metastases [23, 26] . False-negative scans occur in tumors that do not express receptors. Only 38 of 52 pheochromocytomas (73 percent) examined in one study were SSTR positive in vitro [11] . False-negative scans may also occur if tumor somatostatin receptors are down-regulated by endogenous somatostatin production. In one study, 23 of 41 pheochromocytomas tested SRIH positive (56 percent) with three of three of these positive for SRIH mRNA, confirming local production of the hormone [11] . Prior exogenous administration of a somatostatin analogue may also down-regulate receptor expression by tumor. False-negative scans may occur because indium-labeled octreotide is cleared by the kidneys, making imaging of the nearby adrenal glands difficult [23] . Finally, tumors that express a different subtype of somatostatin receptor that the octreotide does not recognize will also be missed by this imaging technique [13, 23] . Octreotide recognizes SSTR2, SSTR3 and SSTR5. Pheochromocytomas rarely overexpress SSTR3 or SSTR5 [5] .
Therefore, imaging is dependent chiefly upon the pheochromocytoma overexpressing SSTR2. In a series of eight pheochromocytomas, SSTR2 and SSTR4 were the most abundantly expressed, but SSTR2 only accounted for 40 percent of the overall SSTR expression by these tumors [5] . [28] . In a separate case report, two patients treated with octreotide (100-150 micrograms subcutaneously every eight hours for five to seven days) had no clinically significant decrease in 24-hour urine free cortisol, serum cortisol or ACTH levels [29] . Thus, short-term therapy of unselected cases of Cushing's with somatostatin analogues is ineffective. Targeting those tumors that overexpress somatostatin receptors based on a positive localization with SRS may prove more effective in specific cases.
Sustained therapy for one month with sandostatin, a long-acting somatostatin analogue (400-1200 micrograms daily intravenous or divided subcutaneously every eight hours for 24-49 days), has proven effective in its ability to decrease the serum ACTH levels of three out of three patients with pituitary Cushing's disease requiring medical therapy [30] . Another patient with paraneoplastic cortisol hypersecretion reported in the same paper was noted to have a significant decrease in serum ACTH levels as well as a sustained decline in urine free cortisol excretion. The literature also contains a single report of a patient who received symptomatic relief from sustained therapy with a somatostatin analogue for a hormonally active, metastatic, adrenal cortical carcinoma that was resistant to standard chemotherapy [31] . Thus, sustained medical therapy with parenteral somatostatin analogues may be considered as an option to provide symptomatic relief to patients with adrenal cortical stimulating tumors who are non-operative candidates. Risks and benefits of this therapy should be balanced with the risks and benefits of more established medical therapies [14] .
Clinical experience with octreotide as a therapeutic agent for pheochromocytoma has not met with success to date. Ten patients with pheochromocytoma in a crossover, placebo-controlled trial were given either three doses of 100 micrograms of octreotide or placebo subcutaneously over 24 hours. Blood pressure and serum and urine catecholamines were monitored pre-and post-dosing. No change in blood pressure or plasma and urine catecholamines were noted overall. Two of the patients with the highest density of somatostatin receptors on their tumors were noted to have a modest decrease in norepinephrine levels, but this did not translate into a lower blood pressure [32] . Other investigators have shown a fall in norepinephrine and epinephrine levels in six patients treated with 50 micrograms of intravenous octreotide infused over two hours, but without a consistent effect on blood pressure [33] .
FUTURE DIRECTIONS A promising area for the therapeutic use of octreotide in adrenal tumor management is to deliver a toxic dose of a radioactive substance directly to tumor cells. Similar technology has been used with 13'I-MIBG, but most tumors respond incompletely and become rapidly resistant to this particular therapy [26, 10] . Radiolabeled somatostatin analogues designed for therapeutic purposes are currently undergoing clinical trials [13] . CONCLUSION In summary, somatostatin receptors are present on both normal adrenal cortex and on tumors producing an excess of adrenal cortical hormones. Imaging of primary adrenal cortical lesions is limited by renal clearance of octreotide and a low somatostatin receptor density. Ectopic or metastatic lesions may be visualized and may partially respond to sustained exogenous treatment with somatostatin analogues. Non-adrenal carcinoid tumors secreting hormones, which stimulate the adrenal gland to overproduce cortisol, are able to be visualized by octreotide. Early use of octreotide scanning may help avoid invasive diagnostic and surgical procedures in patients whose tumors express somatostatin receptors.
The majority of pheochromocytomas and paragangliomas express a high density of somatostatin receptors, and many may be visualized with currently available radiolabeled somatostatin analogues. Further investigation is needed to establish its sensitivity and specificity compared with existing technologies, but clinical use may be considered in patients with documented catecholamine excess and negative or equivocal localization studies.
